Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Masayuki Takanuma"'
Autor:
Takuma Yonemura, Rie Yazawa, Miwa Haranaka, Kazuki Kawakami, Masayuki Takanuma, Takumi Kanzo, Dimitris Stefanidis, Yasumasa Arai
Publikováno v:
BMC Pharmacology and Toxicology, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background FKB327 has been developed as a biosimilar of the adalimumab reference product (RP). We compared the pharmacokinetics (PK), safety, and immunogenicity of FKB327 with those of the adalimumab RP after a single dose by subcutaneous (S
Externí odkaz:
https://doaj.org/article/eeebeba3510b413bb1922f2cbe0455e9
Autor:
Ken Ohta, Mitsuru Adachi, Yuji Tohda, Tadashi Kamei, Motokazu Kato, J. Mark Fitzgerald, Masayuki Takanuma, Tadahiro Kakuno, Nobuyuki Imai, Yanping Wu, Magnus Aurivillius, Mitchell Goldman
Publikováno v:
Allergology International, Vol 67, Iss 2, Pp 266-272 (2018)
Background: In the Phase III CALIMA trial, benralizumab significantly reduced asthma exacerbations, increased lung function, and alleviated symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to
Externí odkaz:
https://doaj.org/article/ada1b0cb627641cb9cc7dec4059d16a2
Publikováno v:
International journal of clinical pharmacology and therapeutics. 60(6)
To compare the pharmacokinetics (PK), safety, tolerability, and immunogenicity of single intravenous doses of FKB238, a proposed biosimilar of bevacizumab, with European Union (EU)-approved and United States (US)-licensed bevacizumab in healthy parti
Autor:
Takuma Yonemura, Rie Yazawa, Miwa Haranaka, Kazuki Kawakami, Masayuki Takanuma, Takumi Kanzo, Dimitris Stefanidis, Yasumasa Arai
Publikováno v:
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 23, Iss 1, Pp 1-11 (2022)
BMC Pharmacology and Toxicology, Vol 23, Iss 1, Pp 1-11 (2022)
Background FKB327 has been developed as a biosimilar of the adalimumab reference product (RP). We compared the pharmacokinetics (PK), safety, and immunogenicity of FKB327 with those of the adalimumab RP after a single dose by subcutaneous (SC) inject
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Phosphate binders (PB) are usually prescribed to dialysis patients with hyperphosphatemia. Several studies have reported that higher PB pill burden may reduce adherence and lead to insufficient phosphorus control. Tenapanor is an
FKB327 is a biosimilar of the adalimumab reference product (RP). The formulation excipients of the FKB327 differ from those of the citrate-containing formulation of the RP, thus injection-site pain (ISP) at subcutaneous injection were assessed in sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73e6352bcaa248a5481c8a1fb6dd33bf
https://doi.org/10.17504/protocols.io.3r2gm8e
https://doi.org/10.17504/protocols.io.3r2gm8e
Autor:
Mitchell Goldman, Motokazu Kato, Tadahiro Kakuno, J. Mark FitzGerald, Yuji Tohda, Mitsuru Adachi, Ken Ohta, Tadashi Kamei, Magnus Aurivillius, Nobuyuki Imai, Yanping Wu, Masayuki Takanuma
Publikováno v:
Journal of Allergy and Clinical Immunology. 139:AB10